Alder BioPharma (ALDR) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alder Biopharm (ALDR) Bullish View Reiterated at Brean Following Q2 Result and Recent Positive ALD403 Data
July 27, 2016 10:36 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and $45 price target on Alder Biopharm (NASDAQ: ALDR) following Q2 results, recent data showing ALD403's durability and Phase 3 data in the 1st-half of 2017.
Aschoff commented, "Alder ended 2Q16 with cash of $450M, which should be able to support operations into 2H18. On Monday, Alder announced positive top-line 24-week data demonstrating sustained migraine... More
Alder Biopharm (ALDR) PT Bumped to $62 at Jefferies as 403 Continues To Advance
July 27, 2016 8:29 AM EDTJefferies analyst Brian Abrahams reiterated a Buy rating and bumped his price target on Alder Biopharm (NASDAQ: ALDR) to $62.00 (from $61.00) as '403 continues to advance.
Abrahams commented, "ALD403 continues to advance on track, and expenses were in line with expectations. Announced... More
